FDA Inspection 1231140 — AptaPharma Inc.

AptaPharma Inc. — FEI 3010164738

The FDA completed an inspection of AptaPharma Inc. on October 24, 2024 in Pennsauken, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
October 24, 2024
Fiscal Year
2025
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Pennsauken, NJ (United States)

Additional Details

Postmarket Adverse Drug Experience (PADE)